

For Immediate Release

Contact: Nonin Public Relations

Phone: 763-553-9968

noninpr@nonin.com

Nonin Medical Announces FDA Clearance for its Next-Generation Regional Oximetry System

Minneapolis, MN – July 13, 2009 – Nonin Medical, Inc., a leading innovator of noninvasive physiological monitoring solutions, announced FDA clearance for its Model 7600 Regional Oximetry System. Introduced in June 2009 at the European Society of Anaesthesiology (ESA) conference in Milan, Italy, the innovative Model 7600 offers real-time monitoring of cerebral oxygenation for patients at risk of ischemia.

Utilizing next-generation near-infrared spectroscopy (NIRS) — Nonin's proprietary EQUANOX™ regional oximetry (rSO₂) technology — the Model 7600 measures oxygen saturation in the cerebral cortex. The innovative sensor design effectively removes surface tissue effects that can influence measurement accuracy — isolating measurements of the cerebral cortex and providing rSO₂ values. The Model 7600 offers industry-leading signal processing to enhance efficiency and an intuitive user interface with Bluetooth® wireless connectivity to streamline file access and storage.

With over 20 years of signal processing and NIRS sensor design expertise, Nonin's innovative technologies enable clinicians to accurately monitor a patient's true condition in the most challenging environments. For more information, go to www.noninequanox.com.

About Nonin Medical Inc. - www.nonin.com

Minneapolis-based Nonin Medical, Inc. is a privately owned company specializing in the design and manufacturing of noninvasive physiological monitoring solutions. Nonin distributes its products to health professionals in more than 125 countries and has over 100 OEM partners worldwide. Nonin's industry-leading capabilities in signal processing and sensor design, plus its on-going integration of features not available in competitive products, are the foundation of its leadership in innovation.